UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
| Date of Report (Date of earliest event reported) | July 30, 2014 |
VACCINOGEN, INC.
(Exact name of registrant as specified in its charter)
| Maryland | 000-54997 | 14-1997223 |
| (State or other jurisdiction | (Commission | (IRS Employer |
| of incorporation) | File Number) | Identification No.) |
5300 Westview Drive, Suite 406, Frederick, MD 21703
(Address of principal executive offices) (Zip Code)
Registrant’s telephone number, including area code:(301) 668-8400
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2.below):
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
| 1 |
Section 1 – Registrant’s Business and Operations
Item 1.01 Entry into a Material Definitive Agreement.
On July 30, 2014, The Abell Foundation provided Vaccinogen with written notice of its agreement to extend until August 15, 2014 the maturity date under the Seventh Amended and Restated Promissory Note made February 1, 2014 by Vaccinogen Inc. in favor The Abell Foundation.
| 2 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| VACCINOGEN INC. | |
| (Registrant) | |
| Date: August 4, 2014 | By:/s/ Michael G. Hanna, Jr., Ph.D. |
| Michael G. Hanna, Jr., Ph.D. | |
| Chief Executive Officer |
| 3 |